Cohen-Kurzrock, Benjamin A.
Cohen, Philip R.
Kurzrock, Razelle
Article History
First Online: 24 May 2016
Competing interests
: R.K. receives research funds from Foundation Medicine, Genentech, Guardant, Merck Serono, Pfizer and Sequenom, consultant fees from Actuate Therapeutics and Sequenom, and has ownership interest in CureMatch and Novena. P.R.C. and B.A.C-K. declare no competing interests.